CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30

CHAMPIONS ONCOLOGY, INC.

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026

$4.69−0.01 (-0.21%)

Close on Oct 19, 2026

Market cap: $65.18M
P/E (TTM): –
Dividend yield: –

CHAMPIONS ONCOLOGY, INC. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-04-30	FY 2025 2025-04-30	FY 2024 2024-04-30	FY 2023 2023-04-30	FY 2022 2022-04-30	FY 2021 2021-04-30	FY 2020 2020-04-30	FY 2019 2019-04-30	FY 2018 2018-04-30	FY 2017 2017-04-30	FY 2016 2016-04-30	FY 2015 2015-04-30	FY 2014 2014-04-30	FY 2013 2013-04-30	FY 2012 2012-04-30	FY 2011 2011-04-30
Depreciation & Amortization	1.40	1.60	1.90	2.10	1.50	0.93	0.83	0.61	0.36	0.17	0.16	0.21	0.21	0.20	–	–
Stock-Based Compensation	1.24	0.65	1.12	0.86	0.91	0.60	0.60	0.64	1.00	2.66	2.60	3.16	2.81	2.38	3.32	3.13
Deferred Income Taxes	0	0	–	–	–	–	–	–	–	–	-3.85	-4.19	-2.16	-2.45	-2.76	0.01
Change in Accounts Receivable	-2.00	-1.44	-1.99	1.31	-2.82	-2.27	-0.67	-0.53	-1.60	-0.99	-0.28	0.27	-0.83	0.08	–	–
Change in Accounts Payable	2.56	-1.75	0.47	2.47	0.97	-1.25	0.33	0.65	0.30	-0.04	0.48	0.43	-0.22	-0.47	0.10	0.64
Change in Unearned Revenue	-6.62	3.35	-0.68	1.71	4.82	0.44	1.79	-0.68	-0.21	1.77	1.13	-0.08	0.98	-0.07	-0.43	0.70
Operating Cash Flow	-4.47	7.39	-6.14	3.97	6.50	-1.68	2.91	1.86	-1.23	-2.84	-6.41	-9.63	-3.43	-4.30	-5.23	-0.05
Capital Expenditures	-0.56	-0.39	-0.84	-2.87	-2.38	-3.28	-2.22	-0.83	-1.23	-0.77	-0.32	-0.12	-0.23	-0.06	-0.52	-0.09
Sale of Property, Plant & Equipment	–	–	–	–	–	–	–	0	0.00	0	0	0.01	0	–	0	0.00
Investing Cash Flow	-0.54	-0.39	-0.84	-2.87	-2.38	-3.17	-2.22	-0.83	-1.23	-0.77	-0.32	-0.11	-0.23	-0.06	-0.52	-0.08
Share Repurchases	–	0	-0.63	-0.07	0	–	–	–	–	–	–	–	–	–	0	-1.03
Stock Issued	–	–	–	–	–	–	–	–	0	4.34	0	0	–	–	–	–
Financing Cash Flow	0.10	0.17	-0.53	0.01	0.21	1.20	4.42	1.20	0.01	4.32	-0.04	13	0.02	9.14	0.10	8.08
Foreign Exchange Rate Adjustments	–	–	–	–	–	–	–	–	–	–	–	0	-0.02	0.03	-0.05	-0.06
Net Change in Cash	-4.91	7.17	-7.50	1.11	4.32	-3.66	5.11	2.23	-2.44	0.71	-6.77	3.47	-3.67	4.81	-5.70	7.89
Free Cash Flow	-5.04	7.00	-6.97	1.10	4.11	-4.96	0.69	1.03	-2.46	-3.61	-6.73	-9.75	-3.67	-4.36	-5.75	-0.14
Income Taxes Paid	0.24	0.04	–	–	–	–	–	–	–	–	–	–	–	0	0	–
Interest Paid	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jul 31, 2026

Profitability, TTM

Gross margin: 49.8%
Operating margin: -1.7%
Net margin: -1.8%
Return on equity, FY2026: -30.5%

Financial strength

Current ratio: 1.03
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 23.3%

Valuation

P/E ratio: –
Price to sales: 1.07
Price to book: 16.74
Dividend yield: –